Candel Therapeutics (NASDAQ:CADL) Stock, Quote.Headers.trade-ideas

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Munich,,Bavaria,,Germany,-,March,31,2023:,Genedx,Holdings,Is

Analyst Color

Biotech

Upgrades

Health Care

Small Cap

Markets

Movers

CADL

CRBP

DAVE

ELEV

JANX

ROOT

SEZL

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)

Rethink Your Budget

News

BRTX

BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property.

Why BioRestorative Therapies Stock Is Moving Higher Thursday

Candel Therapeutics Inc

Cadeler AS

If you've been watching the housing market lately, you've probably noticed that things have gotten pretty complicated even for people with a lot of money. According to an analysis by The Wall Street Journal, more high-earning households are choosing to rent instead of buying a home.&nbsp;
Between 2018 and 2022, the percentage of households earning over $750,000 a year who rent rose to 10.5%, the highest since the mid-2000s. But why are millionaires opting to rent when they could buy?
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
The reasons behind this trend are pretty straightforward. Home prices have skyrocketed to the point where even people making three-quarters of a million dollars a year are finding it tough to justify buying. Mortgage rates have doubled since 2022, making homeownership more expensive than ever.&nbsp;
So, many are asking themselves, &#8220;Wow, I have all this money and I can&#8217;t find a house,&#8221; and &#8220;<a href="https://www.benzinga.com/general/entrepreneurship/24/03/37944606/should-you-rent-or-buy-a-house">Why buy when renting is cheaper?</a>&#8220;
See Also: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
Take George Goognin, a millionaire fintech founder. He moved to the U.S. to buy a home, first in Silicon Valley, then Miami and finally New York. After months of searching and seeing nothing he liked, he rented a luxury three-bedroom apartment in Manhattan for $19,000 a month. He's part of a growing group of high-income earners choosing to rent.
This change is the result of several important factors. First, decent properties are limited and fairly priced even for those with millions to spend. Even for the wealthy, purchasing becomes less appealing financially due to <a href="https://www.benzinga.com/real-estate/24/06/39294393/kevin-oleary-warns-high-mortgage-rates-are-here-to-stay-says-housing-costs-have-gone-up-30-40-percen">high mortgage rates</a>. <a href="https://www.benzinga.com/personal-finance/24/09/40834365/from-cars-and-clothes-to-caskets-renting-is-the-new-normal-for-personal-finance">Renting provides convenience and flexibility</a>, as there is no long-term commitment and no need to worry about upkeep or fluctuations in the market.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Furthermore, some people would rather invest in stocks or other assets than a house, particularly if they don&#8217;t think property values will rise considerably.
It's not just George Goognin. A recent study showed that between 2018 and 2022, the share of renters among households with net worths in the top 5% nearly doubled. That's a significant shift from the past when homeownership was the ultimate goal.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Kris Mullins, Capital Max&#8217;s Chief Marketing Officer, believes that <a href="https://www.benzinga.com/real-estate/24/07/39662917/2024s-hottest-investment-despite-housing-crisis-experts-explain-why-rental-properties-will-make-you">increasing demand makes rental homes a desirable investment</a> because Gen Z and millennials are delaying homeownership or avoiding it altogether, favoring the freedom that renting provides.&nbsp;
Mullins told GoBankingRates, &#8220;With a growing renter pool chasing a potentially limited supply of rental units, vacancy rates are likely to stay low, which translates to consistent rental income for property investors.&#8221;
See Also: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
<a href="https://www.benzinga.com/real-estate/24/06/39293984/grant-cardone-says-owning-rental-properties-will-pay-big-dividends-as-u-s-rents-hit-highest-levels-s">Real estate mogul Grant Cardone agrees</a> with this sentiment. He added, &#8220;baby boomers will trade homeownership for rentals, tapping their equity for travel, investing and later for assisted living.&#8221;&nbsp;
Cardone recommends that individual investors take advantage of the increasing demand for rentals, pointing out that in 50 of the largest cities, renting costs about half as much as owning a home, making rental properties a great investment opportunity.
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>

Real Estate

'Wow, I Have All This Money And I Can't Find A House' – 10.5% Of Households With Annual Incomes Of More Than $750,000 Now Rent

Offerings

ORCL

Oracle Files For Four-part Notes Offering; Size Not Disclosed

WIIM

AIMD

Ainos shares are trading higher after the company announced it has received Institutional Review Board approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients.

RMNI

Rimini Street Ordered To Pay Oracle $58.5M In Attorneys' Fees And Costs By Oct 23 Following District Court Ruling; Rimini Files Notice Of Appeal Against The Award

Northland Capital Markets analyst Mike Grondahl initiates coverage on Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Outperform rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

CIFR

Northland Capital Markets Initiates Coverage On Cipher Mining with Outperform Rating, Announces Price Target of $6

Bill Maher, host of Real Time with Bill Maher, has voiced his strong criticism of cryptocurrency, calling it a major threat to the environment due to its <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36954312/power-hungry-bitcoin-and-other-cryptos-drained-as-much-power-with-mining-as-whole-of-austr">excessive energy consumption</a>.
What Happened: During an <a href="https://x.com/billmaher/status/1838646493118632340">episode</a>, Maher pointed out that the energy usage associated with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining is undoing much of the progress being made in green energy initiatives.
&#8220;All the progress that we&#8217;re making with green energy is being sucked away by crypto,&#8221; Maher remarked, noting that the industry consumes an estimated 8% of the world's electricity. 
Maher highlighted the absurdity of cryptocurrency mining, describing it as &#8220;nonsense of finding a number,&#8221; and drew a stark comparison between crypto&#8217;s energy impact and the environmental cost of traditional fossil fuels.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41014040/from-ceo-to-inmate-caroline-ellison-sentenced-to-24-months-in-ftx-case-what-the-industry-m">From CEO To Inmate: Caroline Ellison Sentenced To 24 Months In FTX Case—What The Industry Must Learn</a>
&#8220;It&#8217;s comparable to putting 15.7 million additional gas-powered cars on the road,&#8221; Maher said, criticizing the environmental burden that crypto imposes.
Maher&#8217;s comments come as the debate around cryptocurrency's carbon footprint intensifies. 
<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41006505/bitcoin-mining-stock-cipher-mining-is-climbing-today-whats-going-on">Bitcoin mining</a>, in particular, has faced scrutiny for its reliance on energy-intensive proof-of-work protocols, which require vast data centers and computational power to validate transactions.
What&#8217;s Next: As the conversation on crypto's environmental footprint heats up, experts and industry leaders will likely tackle these issues at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41012993/sec-charges-trusttoken-and-truecoin-with-fraud-and-unregistered-securities-offering-in-sta">SEC Charges TrustToken And TrueCoin With Fraud And Unregistered Securities Offering In Stablecoin Case</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bill Maher Slams Bitcoin Mining: 'Nonsense Of Finding A Number' Means Green Energy Progress Is Being 'Sucked Away By Crypto'

General

WINT

Windtree Therapeutics Reports Topline Results From Phase 2B SEISMiC Extension Study Of Istaroxime In Early Cardiogenic Shock; Istaroxime Significantly Improves Systolic Blood Pressure Over Six Hours And Shows Notable Secondary Endpoint Improvements

– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – &nbsp;
– Baseline data underscore that alerting agents alone are often insufficient&nbsp;for excessive daytime sleepiness –
DUBLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial. Results demonstrated clinically significant improvements from baseline in wakefulness, overall condition, number of weekly cataplexy episodes, and excessive daytime sleepiness in patients taking LUMRYZ (sodium oxybate) compared to those taking placebo, regardless of concomitant use of alerting agents. The paper, titled "Efficacy of Once-Nightly Sodium Oxybate (FT218) on Daytime Symptoms in Individuals With Narcolepsy With or Without Concomitant Alerting Agent Use: A Post Hoc Analysis From the Phase 3 REST-ON Trial," was published online in <a href="https://www.globenewswire.com/Tracker?data=D9x_8rgnhYOtZIShD2JH65LSU2y_BhURrcJc8Z2ub7Mxzilo6nPlz3cU4yXI9e4AE8sP7miFPl8XWuRbw3gB96ivPtAkn94dMyhQ5s8UQojFFP4MGlX1QRKaRuI9f5sddYl8dhNuX2sdGneP37414uH2hMOCPoqbohxB8A-nDLU=">Sleep Medicine</a>.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Announces Publication Of Data In 'Sleep Medicine' Highlighting Efficacy Of LUMRYZ Extended-Release Oral Suspension In Improving Narcolepsy Symptoms Regardless Of Concomitant Use Of An Alerting Agent

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor &nbsp;
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses
Erasca to host virtual R&amp;D update for investors on Thursday, October 24, 2024, at 8:30 AM ET
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST&#xAE;) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.
Erasca plans to host a virtual investor event to provide a research and development (R&amp;D) update on naporafenib and the RAS targeting franchise on Thursday, October 24, 2024, at 8:30 AM ET in conjunction with the 36th ENA Symposium. A live question and answer session will follow the formal presentation. To register for the event, please click <a href="https://www.globenewswire.com/Tracker?data=4mp2ewsOVezFaoAOBTsostdEy2QWJFnWODvsuPIqh0xCqiMWXd4H7oMfMRDvejotpK72CcQRzWPymGDQW5pG-ehklZu2qHjZJrYcrasLwT0=">here.</a>

ERAS

Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium

Ainos Receives IRB Approval From National Taiwan University Hospital For HIV-Oral Warts Clinical Trial, Showcasing FDA-Designated Orphan Drug VELDONA; Awaits Taiwan FDA Approval To Begin

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose
– Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada
– Submission of the CTA for the Phase 1 clinical study of Normal Healthy Volunteers and ulcerative colitis patients
– On track towards clinical site initiation and dosing of first patient in Phase 1 human clinical study before year end &nbsp;
Carlsbad,&nbsp;CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gPj0tOryZ-1XW_E6RFBEORtv60JdxuEIbv9aJRkFLlwRvmgHOPjp-ojKtMhXtHHVu196onCrTJfCqDvtSXAlvaX_MKdoNecJoT85HqMnBD0=">Palisade Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on its progress toward the launch of its Phase 1 human clinical study for PALI-2108 for the treatment of ulcerative colitis (UC).
The Company's lead program, PALI-2108, is a locally activated PDE4 inhibitor prodrug in development for treating patients with moderate to severely active UC. Leveraging advanced machine learning, the Company's research has identified a measurable threshold of elevated PDE4B expression across more than 1,600 patients and 10 studies, identifying over-expressing patients in over 70% of cases. This finding supports the potential for an FDA-approved test that uses PDE4B expression as a reliable marker for patient enrichment. The Company believes this will lead to better UC patient selection, thereby increasing the efficacy of Palisade's PDE4-inhibiting prodrug therapeutic. Additionally, the Company is advancing a second approach featuring six PDE4-related biomarkers, which has demonstrated superior performance compared to benchmark tests and is specifically tailored for PDE4 inhibition, providing a targeted solution to improve therapeutic outcomes. The integration of PCR-based assays aimed at potential FDA approval will ensure precision in patient targeting. These developments underscore the Company's commitment to leading the field of precision medicine for UC, advancing personalized treatment strategies that promise to transform patient care.

PALI

Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, PALI-2108 For The Treatment Of Ulcerative Colitis; On Track Towards Clinical Site Initiation And Dosing Of First Patient In Phase 1 Human Clinical Study Before Year End

Elon Musk on Tuesday said that his rocket manufacturing company SpaceX will launch close to 90% of all mass to orbit by the end of the year, trumping the competition by a huge margin.
What Happened: &#8220;If the rest of the year goes well, SpaceX will launch close to 90% of all mass to orbit. China will be ~6% and rest of world ~4%,&#8221; Musk wrote on social media platform X. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If the rest of the year goes well, SpaceX will launch close to 90% of all mass to orbit. China will be ~6% and rest of world ~4%.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838627796530467270?ref_src=twsrc%5Etfw">September 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The new outlook provided by the billionaire is slightly lower than his previous forecast. In May, Musk said that SpaceX &#8220;<a href="https://www.benzinga.com/news/24/05/38932200/elon-musk-hopeful-of-spacex-launching-over-90-of-earths-payload-to-orbit-in-2024-nothing-stopping-co">might exceed 90%</a> of all Earth payload to orbit&#8221; this year.
The downgrade is possibly due to the <a href="https://www.benzinga.com/news/24/08/40360084/elon-musks-spacex-meets-its-july-launch-numbers-halfway-through-august-with-back-to-back-launch-miss">two-week pause in SpaceX&#8217;s launch operations</a> in July following a mishap that occurred during a Starlink mission launched on July 11. 
In August, a Falcon 9 booster that supported a Starlink mission <a href="https://www.benzinga.com/news/24/08/40618861/faa-grounds-spacexs-falcon-9-after-booster-fails-to-land-upright-polaris-dawn-launch-timeline-hangs">failed to land upright on a droneship </a>at sea upon returning to Earth and exploded. 
Why It Matters: According to a report from analytics firm Bryce Tech, SpaceX launched about 429,125 kgs of spacecraft upmass in Q1, seconded by China's&nbsp;China Aerospace Science and Technology Corporation&nbsp;(CASC)&nbsp;which launched just 29,426 kgs.&nbsp;SpaceX accounted for roughly 87% of all mass to orbit in the quarter. 
SpaceX&nbsp;<a href="https://www.benzinga.com/news/24/07/39612042/elon-musks-spacex-launches-67-missions-in-first-half-of-2024-trailing-own-targets" target="_blank" rel="noreferrer noopener">completed 67 missions</a>&nbsp;using its Falcon launch vehicles as of the end of the second quarter, with its Falcon 9 workhorse alone accounting for 66 launches and Starlink missions accounting for a major chunk of it.&nbsp;&nbsp;
SpaceX is looking to launch 144 times through the end of the year. For the entirety of last year, SpaceX only completed 96 launches, not including two test flights of the company's Starship launch vehicle.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40899599/elon-musk-said-spacex-competitors-only-take-up-less-than-we-do-and-they-take-nothing-down-and-they-g">Elon Musk Said SpaceX Competitors Only &#8216;Take Up Less Than We Do, And They Take Nothing Down, And They Get Paid Twice As Much&#8217;</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

Elon Musk Adjusts Forecast On SpaceX's Share Of All Mass To Orbit: 'If The Rest Of The Year Goes Well...'

Northland Capital Markets analyst Michael Latimore maintains Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) with a Outperform and raises the price target from $7 to $9.

GRRR

Northland Capital Markets Maintains Outperform on Gorilla Tech Gr, Raises Price Target to $9

Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>), a medical technology company providing therapies for people with chronic disorders, today announced the publication of a new clinical study in the Journal of Vascular Surgery, Venous and Lymphatic Disorders. This study assessed outcomes associated with use of the Company's Flexitouch advanced pneumatic compression device (APCD) in Veterans with lower extremity lymphedema. Notably, this 52-week study represents the largest peer-reviewed, prospective, clinical trial investigating PCDs and lymphedema ever published in the United States.
The prospective, longitudinal, pragmatic study publication, titled "Longitudinal assessment of health-related quality of life and clinical outcomes with at home advanced pneumatic compression treatment of lower extremity lymphedema", was authored by Padberg et al. and included 179 Veterans across four participating VA medical centers. The primary outcome measures included disease-specific health-related quality of life (QoL) endpoints obtained at baseline and again at each of 12, 24, and 52 weeks. The secondary outcome measures assessed limb circumference, cellulitis events, skin quality, and therapy compliance over the course of 52 weeks. Among the patients included in the study, chronic venous insufficiency was the most common etiology of lymphedema (phlebolymphedema), presenting in approximately 63% of study participants. Further, mild lymphedema was the most common disease stage, presenting in 68% of patients.
The secondary endpoint results demonstrated several statistically significant improvements, baseline to 52 weeks, with reductions in limb girth, cellulitis events, and skin hyperpigmentation. Among these results, the following were observed:
<ul>
<li>Limb girth decreased by 1.4 cm</li>
<li>Cellulitis events decreased from 21.4% to 6.1%</li>
<li>Skin hyperpigmentation decreased from 75% of patients to 40%&nbsp; &nbsp;</li>
</ul>
There were additional improvements also noted in compliance and limb girth reduction which included:
<ul>
<li>92% patient compliance (defined as used for 5 to 7 days per week) with Flexitouch at 8 weeks and 72% patient compliance at 52 weeks</li>
<li>74% patient compliance with compression garments at 52 weeks, compared to 64% at baseline
<ul>
<li>6% limb girth reduction at 12 weeks in patients with moderate (stage 2) and severe (stage 3) lymphedema.</li>
</ul>
</li>
</ul>

TCMD

Tactile Medical Announces Clinical Trial Results In Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy; The Secondary Endpoint Results Demonstrated Statistically Significant Improvements, Baseline To 52 Weeks, With Reductions In Limb Girth, Cellulitis Events, And Skin Hyperpigmentation

HRTX

Heron Therapeutics shares are trading higher after the company announced FDA approval of its Prior Approval Supplement application for the ZYNRELEF vial access needle.

Heron Therapeutics Announces FDA Approval Of Co.'s Prior Approval Supplement Application For ZYNRELEF Vial Access Needle

Vice President <a href="https://www.benzinga.com/government/24/09/41019410/long-time-democrat-turned-independent-joe-manchin-withholds-endorsement-for-kamala-harris-this-would">Kamala Harris</a> has moved solidly ahead of Donald Trump, the Republican candidate, in a nationwide poll, while another suggested the two are still running neck-on-neck.
Harris Pulls Ahead: A matchup between Harris and Trump showed 46.6% support for the former among registered voters and 40.48% backing for the latter, the results of the latest Reuters/Ipsos poll conducted on Sept. 21-23 showed. The poll surveyed 1,029 U.S. adults nationwide, which included 871 registered voters. Out of these 785 were considered likely voters. The margin of error is +/- four points.
The vice president has expanded her lead from five points in the previous poll conducted on Sept. 11-12.
Among likely voters, Harris leads Trump by a 50%-46% margin.
The improvement was primarily due to improving voter perception regarding Harris&#8217; ability to shepherd the economy. When registered voters were asked which candidate had the better approach to the &#8220;economy, unemployment and jobs,&#8221; 43% picked Trump and 41% chose Harris. The vice president, though trailing by two points, narrowed her gap vis-a-vis Trump on the front from a three-point deficit in August and an 11-point deficit in late July when she entered the race.
The most recent Reuters/Ipsos poll found that the economy was the number one issue for voters and therefore it doesn&#8217;t come as a surprise that both candidates are vying with each other to feed the electorate with their proposed policy measures.
See Also: <a href="https://www.benzinga.com/news/24/09/40936316/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pro-tr">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a>
CNN Poll Finds Deadlock: A CNN poll conducted by SSRS from Sept. 19-22 among a random nationwide sample of 2,074 registered voters showed, among likely voters, Harris and Trump were almost on an even keel, with the tally at 48%-47% in favor of the former.
Only &nbsp;2% of likely voters said they haven't yet chosen a candidate to support, and another 12% have chosen one but said they could change their minds.
Harris led Trump by a 45%-41% margin among independent likely voters, although gender-wise analysis showed the former with 58% support among independent woman voters compared to 35% support for the latter in this category. Among independent men voters, the tally was 47% to 40% in favor of Trump.
The former president held sway among white voters (58%-35% lead among white men voters and 50%-47% lead among white women voters). On the other hand, voters under 30 years backed Harris by a 55%-38% margin.
The CNN poll found <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41012309/trump-blames-democrats-for-food-inflation-but-experts-suggest-blockchain-could-solve-under">likely voters trust Trump over Harris to handle the economy</a> by a 50%-39% margin. He was also favored for handling immigration and foreign policy. Even among those who said Trump's views and policies are too extreme, 15% said they trust him over Harris to handle the economy and the same share said so on immigration.
Harris&#8217; favorability rating rose to the highest level in CNN polling since just before her and President Joe Biden's inauguration in Jan. 2021. She had a net negative two-point favorability rating compared to a worse net negative 12-point favorability rating for Trump. 
Read Next:
<ul>
<li>Check This Out: Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Wikimedia Commons

Politics

Media

Trump Vs. Harris: Vice President's Favorability Hits Record High, But Faces Setback On This Key Election Issue

Boosting Liquidity And Aligning Interests

Stock Split

NVEE

NV5 Announces 4-For-1 Stock Split To Increase Accessibility For Employees And Investors

BNZI

Banzai International shares are trading lower after the company announced a $5 million private placement.

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.

CDTX

Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) just reported results for the first quarter of 2024.<ul><li>Candel Therapeutics reported earnings per share of -28 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cadl-stock-earnings-candel-therapeutics-for-q1-of-2024/">CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024

Candel Therapeutics GAAP EPS of -$0.28

SCWorx, Cue Health, Sensei Biotherapeutics among healthcare movers

Candel gains FDA orphan status for brain tumor candidate

Candel Therapeutics to join Russell 3000 Index

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Let me be clear: investing in <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> isn&rsquo;t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers high return potential if they make significant advancements in health care.



Biotech stocks represent companies that are involved in the research and development of drugs, therapies and medical devices. They include companies that work in fields such as genomics, biopharmaceuticals, bioinformatics and medical diagnostics.



A-rated biotech stocks are highly coveted because they are at the forefront &mdash; or in the midst of &mdash; groundbreaking innovation. 



A biotech company that wins regulatory approval for a new drug can see a huge increase in stock price, providing lucrative returns to investors and billions of dollars in annual profit for the company.



But remember &mdash; bringing a drug to market costs a lot of money. Biotech stocks must absorb high research and development costs through laboratory research, preclinical trials and multiple phases of clinical trials. 



It can take years to bring a drug to market, or even to get it in front of the Food and Drug Administration for approval. Any setback can derail the drug pipeline and cause the stock price to collapse.



By using the Portfolio Grader, we can identify A-rated biotech stocks based on analyst sentiment, earnings performance, growth and stock buying momentum. If you want to try your hand in the biotech sector, these A-rated biotech stocks are a good place to start.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) can arguably be considered the best biotech stock on the market right now. 



The Indianapolis-based biotech company is set to make billions of dollars a year through its weight-loss treatment drug. And now there&rsquo;s yet another catalyst that is sending LLY stock higher.



First, let&rsquo;s talk about Zepbound, which is Lilly&rsquo;s FDA-approved drug to help people lose weight. The injectable drug won FDA approval in November 2023, so Lilly is just getting started on a long run of profits. About 42% of the U.S. population is obese and the window for Lilly to profit from Zepbound is huge.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes.



The drugs are so popular that Lilly is&nbsp;<a href="https://investor.lilly.com/news-releases/news-release-details/lilly-increases-manufacturing-investment-9-billion-newest">increasing its investment</a>&nbsp;in its Indiana manufacturing facility from $3.7 billion to $9 billion to increase the production of tirzepatide and other pipeline products.



And now Lilly is set to score big on another treatment. An FDA panel voted unanimously in favor of the company&rsquo;s <a href="https://investorplace.com/2024/06/eli-lilly-stock-hits-new-52-week-high-as-fda-panel-recommends-alzheimers-drug/">donanemab&nbsp;</a>drug, which would be used to treat Alzheimer&rsquo;s. The full FDA still needs to give final approval, but the unanimous recommendation of its panel is a very good sign.



LLY stock reached a new 52-week high on the news. The stock is now up 48% on the year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2-300x169.jpg" alt="A close-up concept image of a tiny glass vial with a strand of DNA in it. best biotech stocks"><div>Source: Shutterstock</div></div>Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is a much different biotech company than Lilly. But the company has its own wins and is worthy of its status as an A-rated biotech stock.



Lexaria developed DehydraTECH, which is a drug delivery technology that improves the way active pharmaceutical ingredients enter the bloodstream.



Lexaria says its platform promotes healthier delivery methods and increases the effectiveness of drugs that are delivered by tablets, capsules and oral suspensions.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field. 



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



While R&amp;D costs are still outweighing profits, there&rsquo;s good reason to be bullish on LEXX stock, which is already up 159% this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) has some of the same catalysts are work that are pushing LLY stock higher. 



The European company has an injectable weight loss drug of its own, called Wegovy. Wegovy was approved in 2021 by U.S. regulators to treat weight loss and recently as also approved for treatment in the U.K.



Wegovy&rsquo;s popularity has led to shortages in some pharmacies as Novo Nordisk struggles to keep up with demand. The company&rsquo;s running its manufacturing operations 24 hours a day to meet demand.



Novo Nordisk has another huge drug on the market, Ozempic, which is a treatment for type 2 diabetes.



<a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=168508">Earnings for the first quarter</a> included days of 65.3 billion Danish kroner ($9.46 billion), up 22% from a year ago. Operating profit was up 27%, and net profits were up 29%.



Novo Nordisk reported earnings per share of 5.68 Danish kroner (85 cents per share), which was up 29% from a year ago.



NVO stock is up 38% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/ocgn1600-2-300x169.png" alt="Person holding cellphone with webpage of US biopharmaceutical company Ocugen Inc (OCGN) on screen in front of logo Focus on center of phone display"><div>Source: Wirestock Creators / Shutterstock.com</div></div>Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is a small biotech company based in Pennsylvania. With a market capitalization of less than $400 million, Ocugen is working on developing and commercializing gene and cell therapies.



The company has a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal disease with a single product, which could be highly lucrative if brought to market.



The company has <a href="https://ocugen.com/therapeutic-areas/">multiple retinal products</a> in various phases of testing in an effort to treat hard-to-treat eye disease. 



It also has a treatment in Phase 3 testing to treat knee cartilage damage and ideally help prevent osteoarthritis, and it has started on a potential inhaled vaccine that would help prevent Covid-19.



The company&rsquo;s stock will get a boost later this month when it joins the Russell 3000, an inclusion that should improve the trading volume as funds that track the index purchase OCGN shares.



The company reported <a href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2024-financial">cash and cash equivalents</a> of $25.4 million at the end of the first quarter, with total operating expenses for the quarter of $13.2 million. 



Bringing a drug to market is expensive. But since it has FDA approval for Phase 3 trials for its retinal treatment, the company is on the verge of bringing to market a treatment that affects an estimated 300,000 people in the U.S. and Europe.



OCGN stock still trades for less than $2 per share, but probably won&rsquo;t be that low for long. The stock is up 154% so far in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Candel Therapeutics (CADL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png" alt="Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock"><div>Source: Hernan E. Schmidt / Shutterstock.com</div></div>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) is a Massachusetts that works with viral immunotherapies in an effort to treat cancer. 



Its treatment platform includes combining an anti-tumor component and an immune-stimulatory component to attack malignant cells.



The company developed two clinical stage investigational viral immunotherapies designed to produce an individualized cancer response, based on genetically modified adenovirus and herpes simplex virus gene constructs, respectively.



It currently has several drug candidates in Phase 2 and Phase 3 trials, including treatments for prostate, lung and pancreatic cancer. Like Ocugen, Candel is also joining the Russell 3000 this year.



The company had <a href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2024-financial-results">cash and cash equivalents</a> of $25.7 million at the end of the first quarter, which is says will be sufficient to fund operations into the fourth quarter. R&amp;D expenses in the first quarter were only $4.1 million, while general and administrative expenses were only $3.8 million.



CADL stock soared since April and is now up more than 400% this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Teva Pharmaceutical (TEVA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/teva1600a-300x169.jpg" alt="Opioids Made TEVA Stock Untouchable But Things Seem to be Changing"><div>Source: JHVEPhoto / Shutterstock.com</div></div>Teva Pharmaceutical (NYSE:<a href="https://investorplace.com/stock-quotes/teva-stock-quote/">TEVA</a>) is a leading manufacturer of generic pharmaceuticals. Once a company loses exclusivity in a drug several years after bringing it to market, any drug manufacturer can offer a generic equivalent that can be sold for less than the name-brand drug. That&rsquo;s where Teva comes in.



Teva says nearly 200 million people around the world use drugs that it manufacturers, with production sites in 53 locations spanning 33 countries. The company says its generic equivalents help patients save more than $40 billion a year in health care costs.



One of its <a href="https://investorplace.com/2024/02/teva-stock-pops-4-as-teva-receives-fda-approval/">newest treatments</a> is with a strategic partner, Alvotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/alvo-stock-quote/">ALVO</a>), which won FDA approval for an injectable drug to be used as an alternative to Humira, which is a prescription drug to treat rheumatoid arthritis. 



Humira is made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>), and was one of the biggest pharmaceutical products in the world last year with $12.2 billion in sales.



Revenue for the first quarter was $1.72 billion, up from $1.67 billion a year ago. The company reported profits of $350 million, up from $338 million in the first quarter of 2023.



TEVA stock is up 64% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>GSK (GSK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/gsk-stock-1-300x169.jpg" alt="A GlaxoSmithKline (GSK) office in London."><div>Source: Willy Barton / Shutterstock.com</div></div>GSK (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>), also known as GlaxoSmithKline, is a British biotech company that focuses on making treatments for infectious diseases, HIV, immunology and respiratory conditions and cancer.



Its top drugs include Calpol, which treats cold systems in infants; Ceftum, an antibiotic, and Neosporin, which in cream form treats skin pain, itches and wounds.



The company has more than 70 vaccine candidates and specialty medications in clinical development, with 18 in Phase 3 testing.



Sales in the first quarter were 7.4 billion British pounds ($9.46 billion), up 10% from a year ago. Profits were 2.4 billion British pounds, up 27% from a year ago.



GSK stock is up 11% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier had long positions in NVO and LLY. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-biotech-stocks-worth-betting-on-in-june/">7 A-Rated Biotech Stocks Worth Betting on in June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Biotech Stocks Worth Betting on in June

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

3 Biotech Names With Potential Catalysts By Year End

Candel Therapeutics GAAP EPS of -$0.74

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) just reported results for the second quarter of 2024.<ul><li>Candel Therapeutics reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cadl-stock-earnings-candel-therapeutics-for-q2-of-2024/">CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024

ABBV

AKAN

AMGN

BIIB

FNCH

GNLX

HLTH

LEXX

OCGN

ONMD

RCKT

SNSE

TEVA

VRDN

WORX

Screenshot 2024-06-13 at 5.29.56 PM

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Press Releases

Candel Therapeutics to Join Russell 3000® Index

Opinion

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

Earnings

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

FGEN

HALO

MIST

MRUS

ONCY

REGN

RHHBY

TSX:ONC

VSTM

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Candel Therapeutics

Candel Therapeutics (CADL) Forecast

Candel Therapeutics (NASDAQ:CADL) Stock, Quote.Headers.trade-ideas